Vanda Pharmaceuticals(US:VNDA) Globenewswire·2026-01-20 18:11Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Vanda Pharmaceuticals Inc. and its officers or directors, following a negative FDA decision regarding the approval of HETLIOZ for jet lag disorder [1][3]. Group 1: FDA Decision and Market Reaction - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ could not be approved in its current form, despite acknowledging positive efficacy from clinical trials [3]. - The FDA's decision was based on the view that the clinical trial protocols did not adequately simulate actual jet travel conditions, which involve additional factors such as reduced oxygen pressure and environmental changes [3]. - Following the announcement, Vanda's stock price dropped by $1.20 per share, a decline of 14.05%, closing at $7.34 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Vanda's investors, suggesting potential legal action related to the company's business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]. - The firm has been involved in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [4].